ESMO 2024 – Torl challenges BioNTech in Claudin6
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
ESMO 2024 – a role for immunotherapy in ovarian cancer
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
ESMO 2024 – combos could be the way forward for CDK2
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
Verastem spoils its ASCO bounce
An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.
Volastra vies for the next big synthetic lethality target
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
